Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.

Trial Details

NCT ID
NCT07100730
Phase
PHASE3
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • TLX-101-Tx + Lomustine
  • TLX101-Tx
Locations (sample)
  • Gold Coast, Queensland, Australia|-28.00029,153.43088
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Perth, Western Australia, Australia|-31.95224,115.8614
  • Adelaide, Australia|-34.92866,138.59863
  • Linz, Austria|48.30639,14.28611

Key Eligibility Criteria

  • Previously confirmed neuropathological diagnosis of glioblastoma, IDH-wildtype according to the WHO 2021 classification.
  • Radiographic evidence of first recurrence or progressive glioblastoma according to RANO 2.0 criteria after first-line treatment with biopsy or maxi…
  • Any systemic antineoplastic treatment other than nitroureas
  • Tumor-treating fields

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →